Table 1 Initial characteristics and laboratory features (A, B) and therapy and outcome (C) of the 23 episodes in 21 patients with acute appendicitis.
Parameter | No. of pts. (n = 21) | Percentage |
|---|---|---|
(A) | ||
Gender | ||
Male | 13 | 62 |
Female | 8 | 38 |
Age (years) | ||
Median | 10.21 | |
Range | 1.90–15.78 | |
< 10 | 9 | 43 |
≥ 10 | 12 | 57 |
Primary disease | ||
Acute leukemia# | 15 | 71 |
Solid tumor§ | 4 | 19 |
Aplastic anemia | 2 | 10 |
Previous allogeneic HSCT | ||
Yes | 4 | 19 |
No | 17 | 81 |
Time point after HSCT (months) | ||
Median | 7.68 | |
Range | 0.12–22.08 | |
Parameter | No. of episodes (n = 23) | Percentage |
|---|---|---|
(B) | ||
Clinical symptoms at diagnosis | ||
Abdominal pain | 22 | 96 |
Abdominal tenderness | 4 | 17 |
Fever | 7 | 30 |
Nausea | 2 | 9 |
Emesis | 2 | 9 |
Diarrhea | 5 | 22 |
Constipation | 2 | 9 |
WBC counts (× 10E9/L) at diagnosis | ||
Median | 0.5 | |
Range | 0.2–16.6 | |
ANC (× 10E9/L) at diagnosis | ||
Median | 0.1 | |
Range | 0–14.1 | |
< 0.5 | 17 | 74 |
< 1.5 | 20 | 87 |
Platelet count (× 10E9/L) at diagnosis | ||
Median | 44.0 | |
Range | 6.0–294.0 | |
Corticosteroids at diagnosis | ||
Yes | 6 | 26 |
No | 17 | 74 |
Imaging of appendix | ||
Sonography | 23 | 100 |
Abdominal CT | 3 | 13 |
Abdominal MRI | 2 | 9 |
Thickness (cm) of appendix | ||
Measured | 14 | 61 |
Not measured | 9 | 39 |
Median | 1.0 | |
Range | 0.4–10.7 | |
Blood cultures | ||
Obtained | 9 | 39 |
Not obtained | 14 | 61 |
Positive | 1 (MRSE) | |
Negative | 8 | |
Antibiotics at diagnosis | ||
Yes | 15 | 65 |
No | 8 | 35 |
Antibiotics given | ||
Piperacillin/Tazobactam | 14 | 61 |
Amikacin | 9 | 39 |
Teicoplanin | 2 | 9 |
Vancomycin | 5 | 22 |
Metronidazole | 3 | 13 |
Ceftazidime | 1 | 4 |
Netilmicin | 1 | 4 |
Antimycotics at diagnosis | ||
Yes | 7 | 30 |
No | 16 | 70 |
Antimycotics given | ||
Voriconazole | 4 | 17 |
Liposomal AmB | 2 | 9 |
Fluconazole | 1 | 4 |
Posaconazole | 1 | 4 |
Parameter | No. of episodes (n = 23) | Percentage |
|---|---|---|
(C) | ||
Appendectomy | ||
Yes | 18 | 78 |
No | 5 | 22 |
Histopathology | ||
Compatible with appendicitis | 15 | 83 |
Infiltration with myeloid blasts | 1 | 6 |
Not available | 2 | 11 |
Antibiotic treatment | ||
Piperacillin/Tazobactam | 17 | 74 |
Amikacin | 17 | 74 |
Metronidazole | 16 | 70 |
Vancomycin | 10 | 43 |
Meropenem | 9 | 39 |
Ceftazidime | 9 | 39 |
Teicoplanin | 6 | 26 |
Linezolid | 5 | 22 |
Netilmicin | 2 | 9 |
Others | 8 | 35 |
Antifungal treatment | ||
None | 7 | 30 |
Liposomal AmB | 7 | 30 |
Fluconazole | 7 | 30 |
Voriconazole | 4 | 17 |
Posaconazole | 2 | 9 |
Itraconazole | 1 | 4 |
ANC (× 10E9/L) at the time of surgery | ||
Median | 0.7 | |
Range | 0–14.1 | |
< 0.5 | 7 | 39 |
< 1.5 | 11 | 48 |
Platelet count (× 10E9/L) at the time of surgery | ||
Median | 113.5 | |
Range | 11.0–297.0 | |
Transfusion of granulocytes (days) | ||
Yes | 7 | 30 |
No | 16 | 70 |
Median | 5 | |
Range | 3–12 | |
Therapy with G-CSF | ||
Yes | 15 | 65 |
No | 8 | 35 |
Time to appendectomy (days) | ||
Median | 5 | |
Range | 0–31 | |
Duration until restart of chemotherapy (days) | ||
Median | 17 | |
Range | 0–61 | |
Outcome | ||
Alive | 18 | 78 |
Dead | 5 | 22 |
HSCT-related | 2 | |
Leukemia-related | 2 | |
Appendicitis/typhlitis | 1 | |
Follow-up of surviving patients (years) | ||
Median | 6.75 | |
Range | 0.16–12.71 | |
